Associate Director/ Director FP&A EMEA

About the role

The Associate Director/ Director, FP&A will support the EMEA organization by serving as a strategic partner in framing, evaluating, and driving financial decisions. This role involves planning and delivering against financial objectives while collaborating with cross-functional stakeholders to maximize value creation. The position offers the opportunity to build critical financial capabilities within a growing biotechnology company.

Responsibilities

• Serve as the primary finance partner for the EMEA scope across revenue and OPEX planning.
• Support FP&A activities including budgeting and forecasting, long-range planning, scenario modeling, and financial analysis for strategic initiatives.
• Build and maintain patient and revenue models, ensuring appropriate underlying assumptions for direct and partner markets.
• Partner with EMEA Accounting on month-end and quarter-end close activities, quarterly schedules, procure-to-pay processes, and support for external reporting and audit inquiries.
• Deliver timely monthly budget-to-actual analyses, including variance analysis and management reporting.
• Drive continuous improvement of FP&A processes to increase efficiency while maintaining flexibility to meet evolving business needs.
• Develop and deliver training and change-management support to drive adoption of new FP&A tools, systems, and ways of working across the organization.
• Support ad hoc strategic initiatives as business needs arise, including business development analyses, partner support, portfolio prioritization, and financing strategies.

Required skills

• FP&A
• Financial analysis
• Budgeting
• Forecasting
• Revenue modeling
• Accounting principles
• Excel
• English

Nice to have

• Adaptive Insights
• SAP
• European languages

Qualifications

• Bachelor’s degree and 8+ years of progressive finance experience in the pharmaceutical or biotechnology industry
• Advanced degree in science and/or business

About the Company

Scholar Rock is a biopharmaceutical company focused on developing muscle-targeted breakthroughs to treat spinal muscular atrophy and other rare neuromuscular diseases. The company utilizes a proprietary platform to develop novel monoclonal antibodies that modulate protein growth factors.